Compelling evidence for unconditional shift to dolutegravir

doi:10.1016/S2352-3018(22)00164-3

Comment

. 2022 Aug;9(8):e523-e524.

doi: 10.1016/S2352-3018(22)00164-3.

Compelling evidence for unconditional shift to dolutegravir

Kim Steegen¹, Lucia Hans²

Affiliations

¹ Department of Haematology and Molecular Medicine, National Health Laboratory Services, Johannesburg, South Africa; Department of Haematology and Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa; Charlotte Maxeke Johannesburg Academic Hospital, 2193 Parktown, Johannesburg, South Africa. Electronic address: kim.steegen@nhls.ac.za.
² Department of Haematology and Molecular Medicine, National Health Laboratory Services, Johannesburg, South Africa; Department of Haematology and Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa; Charlotte Maxeke Johannesburg Academic Hospital, 2193 Parktown, Johannesburg, South Africa.

PMID: 35905750
DOI: 10.1016/S2352-3018(22)00164-3

Comment

Compelling evidence for unconditional shift to dolutegravir

Kim Steegen et al. Lancet HIV. 2022 Aug.

. 2022 Aug;9(8):e523-e524.

doi: 10.1016/S2352-3018(22)00164-3.

Authors

Kim Steegen¹, Lucia Hans²

Affiliations

¹ Department of Haematology and Molecular Medicine, National Health Laboratory Services, Johannesburg, South Africa; Department of Haematology and Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa; Charlotte Maxeke Johannesburg Academic Hospital, 2193 Parktown, Johannesburg, South Africa. Electronic address: kim.steegen@nhls.ac.za.
² Department of Haematology and Molecular Medicine, National Health Laboratory Services, Johannesburg, South Africa; Department of Haematology and Molecular Medicine, University of the Witwatersrand, Johannesburg, South Africa; Charlotte Maxeke Johannesburg Academic Hospital, 2193 Parktown, Johannesburg, South Africa.

PMID: 35905750
DOI: 10.1016/S2352-3018(22)00164-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Schramm B, Temfack E, Descamps D, Nicholas S, Peytavin G, Bitilinyu-Bangoh JE, Storto A, Lê MP, Abdi B, Ousley J, Kalua T, Calvez V, Jahn A, Marcelin AG, Szumilin E. Schramm B, et al. Lancet HIV. 2022 Aug;9(8):e544-e553. doi: 10.1016/S2352-3018(22)00136-9. Lancet HIV. 2022. PMID: 35905753

Cited by

Longer-term virologic outcomes on tenofovir-lamivudine-dolutegravir in second-line ART.
van Heerden JK, Zhao Y, Keene CM, Griesel R, Omar Z, Goliath R, Delaney K, van Zyl G, Maartens G, Meintjes G. van Heerden JK, et al. South Afr J HIV Med. 2025 Apr 30;26(1):1677. doi: 10.4102/sajhivmed.v26i1.1677. eCollection 2025. South Afr J HIV Med. 2025. PMID: 40356938 Free PMC article.
Geospatial and temporal mapping of detectable HIV-1 viral loads amid dolutegravir rollout in KwaZulu-Natal, South Africa.
Gounder L, Tomita A, Lessells R, Moodley S, Francois KL, Khan A, Pillay M, Manyana SC, Govender S, Govender K, Moodley P, Parboosing R, Msomi N, Tanser F, Naidoo K, Chimukangara B. Gounder L, et al. PLOS Glob Public Health. 2024 May 28;4(5):e0003224. doi: 10.1371/journal.pgph.0003224. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 38805477 Free PMC article.
Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.
Zaniewski E, Skrivankova VW, Brazier E, Avihingsanon A, Wagner Cardoso S, Cesar C, Chenal H, Crabtree-Ramírez BE, Ditangco RA, Ebasone PV, Eley B, Euvrard JG, Fatti G, Huwa JM, Lelo P, Machado DM, Messou EK, Minga AK, Muleebwa J, Mundhe S, Murenzi G, Muyindike WR, Nsonde DM, Obatsa SM, Odhiambo J, Prozesky HW, Rungmaitree S, Semeere AS, Seydi M, Sipambo N, Sudjaritruk T, Technau KG, Tiendrebeogo T, Twizere C, Ballif M. Zaniewski E, et al. AIDS. 2024 Dec 1;38(15):2073-2085. doi: 10.1097/QAD.0000000000004007. Epub 2024 Sep 26. AIDS. 2024. PMID: 39236112 Free PMC article.
The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study.
Al Naimi A, Chang C, Rawizza H, Olaifa O, Ogunsola O, Okonkwo P, Kanki P. Al Naimi A, et al. J Obstet Gynaecol Res. 2025 Jun;51(6):e16349. doi: 10.1111/jog.16349. J Obstet Gynaecol Res. 2025. PMID: 40545832 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Compelling evidence for unconditional shift to dolutegravir

Affiliations

Compelling evidence for unconditional shift to dolutegravir

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical